GI Dynamics, Inc. (ASX: GID) is the developer and marketer of EndoBarrier^®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S.; and GI Dynamics is conducting a pivotal clinical trial of EndoBarrier (the ENDO Trial)  in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts, with offices in Europe and Australia.

Through its patented EndoBarrier^® Therapy, GI Dynamics is poised to address the growing diabetes and obesity patient populations, which have reached epidemic proportions and represent two of the largest healthcare markets globally.